The global Inhaled Nitric Oxide market size was US$ 1270 million in 2024 and is forecast to a readjusted size of US$ 2202 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
The global Inhaled Nitric Oxide market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
By Type: (Dominant Segment vs High-Margin Innovation)
800 ppm
100 ppm
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Mallinckrodt in Europe)
- Emerging Product Trends: 800 ppm adoption vs. 100 ppm premiumization
- Demand-Side Dynamics: Near-term and Pre-term Infants PPHN growth in China vs. Children and Adult ARDS potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Inhaled Nitric Oxide market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., 100 ppm in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Children and Adult ARDS in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., 800 ppm dominance in Europe vs. 100 ppm demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Inhaled Nitric Oxide Product Scope
1.2 Inhaled Nitric Oxide by Type
1.2.1 Global Inhaled Nitric Oxide Sales by Type (2020 & 2024 & 2031)
1.2.2 800 ppm
1.2.3 100 ppm
1.2.4 Others
1.3 Inhaled Nitric Oxide by Application
1.3.1 Global Inhaled Nitric Oxide Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Near-term and Pre-term Infants PPHN
1.3.3 Children and Adult ARDS
1.3.4 Other Diseases
1.4 Global Inhaled Nitric Oxide Market Estimates and Forecasts (2020-2031)
1.4.1 Global Inhaled Nitric Oxide Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Inhaled Nitric Oxide Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Inhaled Nitric Oxide Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Inhaled Nitric Oxide Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Inhaled Nitric Oxide Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Inhaled Nitric Oxide Sales Market Share by Region (2020-2025)
2.2.2 Global Inhaled Nitric Oxide Revenue Market Share by Region (2020-2025)
2.3 Global Inhaled Nitric Oxide Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Inhaled Nitric Oxide Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Inhaled Nitric Oxide Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Inhaled Nitric Oxide Market Size and Prospective (2020-2031)
2.4.2 Europe Inhaled Nitric Oxide Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Inhaled Nitric Oxide Historic Market Review by Type (2020-2025)
3.1.1 Global Inhaled Nitric Oxide Sales by Type (2020-2025)
3.1.2 Global Inhaled Nitric Oxide Revenue by Type (2020-2025)
3.1.3 Global Inhaled Nitric Oxide Price by Type (2020-2025)
3.2 Global Inhaled Nitric Oxide Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Inhaled Nitric Oxide Sales Forecast by Type (2026-2031)
3.2.2 Global Inhaled Nitric Oxide Revenue Forecast by Type (2026-2031)
3.2.3 Global Inhaled Nitric Oxide Price Forecast by Type (2026-2031)
3.3 Different Types Inhaled Nitric Oxide Representative Players
4 Global Market Size by Application
4.1 Global Inhaled Nitric Oxide Historic Market Review by Application (2020-2025)
4.1.1 Global Inhaled Nitric Oxide Sales by Application (2020-2025)
4.1.2 Global Inhaled Nitric Oxide Revenue by Application (2020-2025)
4.1.3 Global Inhaled Nitric Oxide Price by Application (2020-2025)
4.2 Global Inhaled Nitric Oxide Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Inhaled Nitric Oxide Sales Forecast by Application (2026-2031)
4.2.2 Global Inhaled Nitric Oxide Revenue Forecast by Application (2026-2031)
4.2.3 Global Inhaled Nitric Oxide Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Inhaled Nitric Oxide Application
5 Competition Landscape by Players
5.1 Global Inhaled Nitric Oxide Sales by Players (2020-2025)
5.2 Global Top Inhaled Nitric Oxide Players by Revenue (2020-2025)
5.3 Global Inhaled Nitric Oxide Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inhaled Nitric Oxide as of 2024)
5.4 Global Inhaled Nitric Oxide Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Inhaled Nitric Oxide, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Inhaled Nitric Oxide, Product Type & Application
5.7 Global Key Manufacturers of Inhaled Nitric Oxide, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Inhaled Nitric Oxide Sales by Company
6.1.1.1 North America Inhaled Nitric Oxide Sales by Company (2020-2025)
6.1.1.2 North America Inhaled Nitric Oxide Revenue by Company (2020-2025)
6.1.2 North America Inhaled Nitric Oxide Sales Breakdown by Type (2020-2025)
6.1.3 North America Inhaled Nitric Oxide Sales Breakdown by Application (2020-2025)
6.1.4 North America Inhaled Nitric Oxide Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Inhaled Nitric Oxide Sales by Company
6.2.1.1 Europe Inhaled Nitric Oxide Sales by Company (2020-2025)
6.2.1.2 Europe Inhaled Nitric Oxide Revenue by Company (2020-2025)
6.2.2 Europe Inhaled Nitric Oxide Sales Breakdown by Type (2020-2025)
6.2.3 Europe Inhaled Nitric Oxide Sales Breakdown by Application (2020-2025)
6.2.4 Europe Inhaled Nitric Oxide Major Customer
6.2.5 Europe Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Mallinckrodt
7.1.1 Mallinckrodt Company Information
7.1.2 Mallinckrodt Business Overview
7.1.3 Mallinckrodt Inhaled Nitric Oxide Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Mallinckrodt Inhaled Nitric Oxide Products Offered
7.1.5 Mallinckrodt Recent Development
7.2 Praxair (Linde plc)
7.2.1 Praxair (Linde plc) Company Information
7.2.2 Praxair (Linde plc) Business Overview
7.2.3 Praxair (Linde plc) Inhaled Nitric Oxide Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Praxair (Linde plc) Inhaled Nitric Oxide Products Offered
7.2.5 Praxair (Linde plc) Recent Development
7.3 Air Liquide
7.3.1 Air Liquide Company Information
7.3.2 Air Liquide Business Overview
7.3.3 Air Liquide Inhaled Nitric Oxide Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Air Liquide Inhaled Nitric Oxide Products Offered
7.3.5 Air Liquide Recent Development
7.4 BOC Healthcare (Linde Group)
7.4.1 BOC Healthcare (Linde Group) Company Information
7.4.2 BOC Healthcare (Linde Group) Business Overview
7.4.3 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Sales, Revenue and Gross Margin (2020-2025)
7.4.4 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Products Offered
7.4.5 BOC Healthcare (Linde Group) Recent Development
8 Inhaled Nitric Oxide Manufacturing Cost Analysis
8.1 Inhaled Nitric Oxide Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Inhaled Nitric Oxide
8.4 Inhaled Nitric Oxide Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Inhaled Nitric Oxide Distributors List
9.3 Inhaled Nitric Oxide Customers
10 Inhaled Nitric Oxide Market Dynamics
10.1 Inhaled Nitric Oxide Industry Trends
10.2 Inhaled Nitric Oxide Market Drivers
10.3 Inhaled Nitric Oxide Market Challenges
10.4 Inhaled Nitric Oxide Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
Ìý
Ìý
*If Applicable.